the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 218 participants.

Also called NCT06650007

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 218 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06650007
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06650007. Randomized; double masking; primary purpose treatment. Start 2024-11-08 (actual); primary completion 2026-01-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes, Inadequately Controlled With Diet and Exercise Alone
Condition
Diabetes Mellitus, Type 2
Intervention (Drug)
HRS9531 Injection
Intervention (Drug)
HRS9531 Placebo Injection
Lead sponsor
Fujian Shengdi Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct06650007
Content hash
ed979640be845806a34c7e4f28d89d6a7c2a4b87958698e531cfa390f8821394